Trying to Reduce the Uncertainty Surrounding Phosphorus Binders
I would wager that pound-for-pound, there is no drug with less solid outcome-based data than phosphorus binders. We are aware that phosphorus binders do an acceptable job of [...]
bone disease
#SCM16: Velphoro in ESRD
Dr. Stuart M. Sprague (SMS), from NorthShore University Health System University of Chicago Pritzker School of Medicine (Evanston, Illinois), discusses his abstracts for the [...]
Biomarkers and Thresholds to Identify Bone Turnover: A Retrospective Cohort Study of Bone Biopsies
Bone mineral disease (MBD) is common in patients with chronic kidney disease (CKD), yet remains a diagnostic and therapeutic enigma for clinicians and scientists. In contrast [...]
Calciphylaxis – What Do We Know?
Calciphylaxis is a rare and devastating disease, affecting mostly patients with end-stage kidney disease, but also affecting patients with preserved kidney function. Due to [...]
Test Your Knowledge: CRS and the Role of Bone-Mineral Axis & Anemia
There has been longstanding recognition of the relationship between CKD and cardiovascular morbidity and mortality. More recently, the term “cardiorenal syndrome” has [...]
FGF-23 and Sudden Cardiac Death
Cardiovascular death and chronic kidney disease (CKD) are strongly linked, but there are few clear mechanisms that explain the reason for this association. Even in the early [...]
Effect of eGFR on Vitamin D Metabolism: A Participant-Level Data Analysis of 5 Cohort Studies
Invited commentary from Dr. Sairah Sharif It is appreciated that CKD leads to reduced production of active 1,25-dihydroxyvitamin D3 (1,25(OH)D3). However the effects of [...]
Test Your Knowledge: Bone Disease and CKD
Osteoporosis and fractures are common in chronic kidney disease (CKD). While the diagnosis and management of osteoporosis is similar in patients with CKD stages 1-3 as in [...]
SCM14: Paricalcitol vs Calcitriol, Let’s PACE It
Dr. Daniel Coyne (DC), from Washington University School of Medicine, discusses his abstract for the National Kidney Foundation’s 2014 Spring Clinical Meetings (SCM14), [...]
Ferric Citrate and Hyperphosphatemia
AJKD recently published an article from Dwyer et al on a dose-response and safety/tolerability trial of a novel phosphorous binder, ferric citrate, for dialysis patients. [...]